Kim R. Tsuchimoto - Jul 14, 2025 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Director
Signature
/s/ Quan Vu, Attorney-in-fact
Stock symbol
MNPR
Transactions as of
Jul 14, 2025
Transactions value $
-$356,126
Form type
4
Date filed
7/16/2025, 09:06 PM
Previous filing
Mar 7, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Tsuchimoto Kim R Director 1000 SKOKIE BLVD SUITE 350, WILMETTE /s/ Quan Vu, Attorney-in-fact 2025-07-16 0001333516

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNPR Common Stock Exercise of in-the-money or at-the-money derivative security $44.50 +8.9K +77.52% $0.01 20.4K Jul 14, 2025 Direct F1
transaction MNPR Common Stock Sale -$356K -8.9K -43.67% $40.00 11.5K Jul 14, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Stock Options Exercise of in-the-money or at-the-money derivative security $0 -4.2K -100% $0.00 0 Jul 14, 2025 Common Stock 4.2K $0.01 Direct F3
transaction MNPR Stock Options Exercise of in-the-money or at-the-money derivative security $0 -4.7K -100% $0.00 0 Jul 14, 2025 Common Stock 4.7K $0.01 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction involved a cash exercise of stock options.
F2 The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3 Reflects options to purchase a total of 4,200 shares of common stock granted to Ms. Tsuchimoto on April 4, 2016, for her services as a director and prior officer of Monopar Therapeutics.The options vested 6/12ths upon the grant date and 3/12th every 6 months thereafter.
F4 Reflects options to purchase a total of 4,704 shares of common stock granted to Ms. Tsuchimoto on February 20, 2017, for her services as a director and prior officer of Monopar Therapeutics. The options vested 6/48ths upon the 6-month anniversary of the grant date and 1/48th per month thereafter.